Insights into biotechnology with Gregg Guerin and Ryan Issakainen

Investors are now fully aware of the importance that biotechnology companies can have in their portfolios. 2020 presented a fascinating backdrop for the biotech industry with some key updates across regulatory and M&A. The last six months has seen the industry help society mitigate the pandemic by developing testing kits, vaccines and therapeutics. But what are the implications for Biotech with a U.S. election just around the corner? Ryan Issakainen & Gregg Guerin provide some fascinating insight into how this sector has benefitted historically and the short term implications. Some important tailwinds have come into play this year, providing a boost to the sector as a whole, including: U.S. regulators removing red tape surrounding the speed at which new cures & vaccines can hit the market The FDA Commissioner has said: “Permanent change, where needed, will take place” 2017, 2018 and 2019 have been three of the most productive years for drug approvals in the last 20 years M&A activity remains fertile with the cash reserves held by our index names extremely high There are many areas of day-to-day life that are influenced by biotechnology, as the two longest running megatrends in human history combine, we explore the key potential positive implications for the First Trust NYSE ARCA Biotechnology UCITS ETF. The FDA Commissioner has said: “Permanent change, where needed, will take place” 2017, 2018 and 2019 have been three of the most productive years for drug approvals in the last 20 years M&A activity remains fertile with the cash reserves held by our index names extremely high There are many areas of day-to-day life that are influenced by biotechnology, as the two longest running megatrends in human history combine, we explore the key potential positive implications for the First Trust NYSE ARCA Biotechnology UCITS ETF.